Alexander's, Inc. ALX
238.72 USD -3.04 (-1.26%)
As ofNov 17, 2026, 11:43 AM EST
236.49 Day range 240.55
201.28 52-week range 289.43
- YTD
- +9.53%
- 1 year
- +12.94%
News
globenewswire.com ALX Oncology Reports Third Quarter 2026 Financial Results and Provides Corporate Update Expect to report safety and early efficacy data from the Phase 1 dose-escalation study of ALX2004 in EGFR-expressing solid tumors and plan to host a KOL webinar to review the results in December 2026…
globenewswire.com ALX Oncology to Present at Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel…
benzinga.com Alexander's Q3 2026 Earnings Call Transcript Alexander’s (NYSE:ALX) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com Alexander's Q3 FFO $7.07 Misses $8.20 Estimate, Sales $72.056M Miss $82.400M Estimate Alexander's (NYSE:ALX) reported quarterly earnings of $7.07 per share which missed the analyst consensus estimate of $8.20 by 13.78 percent. This is a 142.96 percent increase over earnings of $2.91…
